Therapy News and Research

RSS

Repligen 2011 second quarter total revenue increases 35% to $7,307,000

Repligen Corporation today reported results for the second quarter of fiscal year 2011, ended September 30, 2010.

2 Nov 2010

Fresenius third quarter net revenue increases 6% to $3,058 million

Fresenius Medical Care AG & Co. KGaA: Net revenue for the third quarter of 2010 increased by 6% to $3,058 million compared to the third quarter of 2009. Organic revenue growth worldwide was 6%.

2 Nov 2010

Elekta presents solutions for ultimate precision in cancer care at ASTRO Meeting

Elekta presented solutions for ultimate precision in cancer care at an Investor Meeting in conjunction with the 52nd annual American Society for Radiation Oncology (ASTRO) Meeting, in San Diego. Elekta also discussed the market drivers in established and emerging markets, and explained its strategy for sustainable profitable growth.

From Elekta 2 Nov 2010

African Americans more likely to have uterine cancer recurrence

African Americans are more likely to have a recurrence of uterine cancer despite undergoing a total hysterectomy or a hysterectomy followed by radiation therapy, according to researchers at Henry Ford Hospital in Detroit.

2 Nov 2010

New targeted therapy shows positive results in patients with lung cancer

A UC Irvine oncologist's work with a targeted therapy is showing great promise in patients with a deadly form of lung cancer. The results were published Thursday in the New England Journal of Medicine.

2 Nov 2010

Micronutrient Initiative receives $75 million to expand innovative nutrition programming

Minister of International Cooperation, Beverley Oda, has announced $75 million in new funding for the work of the Micronutrient Initiative to expand innovative nutrition programming and strengthen African health systems. The investment will be spread over five years and is expected to benefit 4 million pregnant women and 14 million children under the age of five - particularly in sub-Saharan Africa.

2 Nov 2010

Elekta awarded delivery of three Leksell Gamma Knife systems to Chinese hospitals

In winning a tender to deliver three Leksell Gamma Knifeâ models to hospitals in China, Elekta will help more cancer patients receive the therapy they need. The agreement also helps Elekta increase its leading market position in China.

From Elekta 2 Nov 2010

Provident launches Principals Fund I with $25 million of committed capital

Provident Healthcare Ventures, LLC is pleased to announce the launch of its inaugural Principals Fund I with $25 million of committed capital. All capital invested in the Fund will be provided by the principals of Provident, affirming their belief that providing early-stage healthcare services companies with crucial resources, such as capital and operating expertise, will significantly increase enterprise value over the life of the investment.

2 Nov 2010

$Hypofractionated IMRT therapy does not increase side effects in prostate cancer patients$

Hypofractionated IMRT therapy does not increase side effects in prostate cancer patients

When treating prostate cancer with radiation therapy, side effects such as urinary problems and rectal pain and bleeding are a concern, as is impact on the patient's overall quality of life. So when new, more efficient treatment methods are developed, one important question is whether better treatment comes at the cost of increased side effects and decreased quality of life.

2 Nov 2010

Positive preliminary data from Protalix's taliglucerase alfa switchover trial for Gaucher disease

Protalix BioTherapeutics, Inc., announced today positive preliminary data from the first 15 patients that completed the Company's nine month, worldwide, multi-center, open-label, switchover trial of taliglucerase alfa for the treatment of Gaucher disease under a protocol cleared by the U.S. Food and Drug Administration (FDA). The data indicate that patients can safely be switched to taliglucerase alfa from imiglucerase (Cerezyme®).

2 Nov 2010

Innovative lifesaving device for patients with advanced heart failure

Bradley Cantley, 41, headed home from UC San Diego Medical Center connected to a lifesaving heart machine called a left ventricular assisted device (LVAD). For patients with advanced heart failure, the mechanical pump rapidly improves circulation throughout the body and serves as a bridge to transplant. Cantley is the first of many patients, locally and globally, who will benefit from the expanded heart surgery program at UC San Diego Health System.

2 Nov 2010

FDA selects Rochester to lead initiative to identify improved pain treatments

Pain is the most common symptom leading patients to see a physician in the United States, yet the most widely prescribed medications - opioids and non-steroidal anti-inflammatory drugs (NSAIDS) - have major drawbacks, including the potential for misuse and abuse and adverse effects that limit long-term use. While scientists have made great strides in understanding the physical and chemical processes that occur when people feel pain, new treatments with improved safety and effectiveness are still needed for the more than 76 million Americans with acute and chronic pain.

2 Nov 2010

ADVANCE Phase 3 study confirms clinical benefits of telaprevir regimen in patients with HCV infection

The Phase 3 results from the ADVANCE study confirm the clinical benefits of telaprevir-based combination therapy regimens. The study reports an improvement in treatment discontinuation rates due to adverse events compared to Phase 2 studies, and demonstrates an increase in sustained viral response (SVR) in patients with hepatitis C virus (HCV). The primary endpoint for this study was SVR 24 weeks after last treatment.

2 Nov 2010

Teva third quarter net sales increase 20% to $4.3 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended September 30, 2010.

2 Nov 2010

Boceprevir combinational therapy improves SVR rate in patients with HCV genotype 1

The final results of the RESPOND-2 trial demonstrated that combination therapy with Boceprevir yields higher sustained virologic response (SVR) rates for patients with hepatitis C virus (HCV) genotype 1 who did not respond to or relapsed after treatment with peginterferon alpha 2b and Ribavirin.

2 Nov 2010

Research on AID enzyme could improve therapy for lymphoma, leukemia

A recent scientific discovery made by researchers at the Institut de recherches cliniques de Montr-al (IRCM) led by Dr. Javier Marcelo Di Noia, Director of the Mechanisms and Genetic Diversity research unit, was published online today by The Journal of Experimental Medicine. The team identified a mechanism regulating activation-induced deaminase (AID), which could be important for the therapy of some types of lymphoma and leukemia.

2 Nov 2010

BioCancell's Phase I/IIa clinical trial of BC-819 shows positive result for pancreatic cancer

BioCancell, a developer of anti-cancer drugs, announced success in attaining the goals of its Phase I/IIa clinical trial of BC-819 as a treatment for pancreatic cancer, which demonstrated an excellent safety profile and preliminary efficacy.

2 Nov 2010

Researchers investigate Human-cl rhFVIII factor for severe hemophilia A treatment

Octapharma AG, one of the largest human protein products manufacturers in the world, and Octapharma USA today announced that patients diagnosed with severe hemophilia A have started treatment in a multi-center study that is researching the use of the first recombinant Factor VIII (rFVIII) derived from a human cell line (Human-cl rhFVIII).

2 Nov 2010

Rubicon's PicoPlex kits provide DNA methylation profiling using next-generation sequencing

Rubicon Genomics today reported data demonstrating that its PicoPlex kits currently marketed for the analysis of single cells for research and diagnostic applications also provide important advantages for genetic and epigenetic profiling using next-generation sequencing (NGS).

2 Nov 2010

ISHIB releases new recommendations to manage hypertension in African Americans

Through the publication of its Consensus Statement on the Management of High Blood Pressure in Blacks in this week's issue of Hypertension, ISHIB today released new recommendations recognizing that high blood pressure among African Americans is a severe health problem. The consensus statement suggests that treatment should start sooner and be more aggressive among African Americans.

2 Nov 2010

Therapy News and Research

Repligen 2011 second quarter total revenue increases 35% to $7,307,000

Fresenius third quarter net revenue increases 6% to $3,058 million

Elekta presents solutions for ultimate precision in cancer care at ASTRO Meeting

African Americans more likely to have uterine cancer recurrence

New targeted therapy shows positive results in patients with lung cancer

Micronutrient Initiative receives $75 million to expand innovative nutrition programming

Elekta awarded delivery of three Leksell Gamma Knife systems to Chinese hospitals

Provident launches Principals Fund I with $25 million of committed capital

Hypofractionated IMRT therapy does not increase side effects in prostate cancer patients

Positive preliminary data from Protalix's taliglucerase alfa switchover trial for Gaucher disease

Innovative lifesaving device for patients with advanced heart failure

FDA selects Rochester to lead initiative to identify improved pain treatments

ADVANCE Phase 3 study confirms clinical benefits of telaprevir regimen in patients with HCV infection

Teva third quarter net sales increase 20% to $4.3 billion

Boceprevir combinational therapy improves SVR rate in patients with HCV genotype 1

Research on AID enzyme could improve therapy for lymphoma, leukemia

BioCancell's Phase I/IIa clinical trial of BC-819 shows positive result for pancreatic cancer

Researchers investigate Human-cl rhFVIII factor for severe hemophilia A treatment

Rubicon's PicoPlex kits provide DNA methylation profiling using next-generation sequencing

ISHIB releases new recommendations to manage hypertension in African Americans

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News